Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

TRC105 is an endoglin-targeting drug that possesses anti-angiogenic and antitumor potential. Analysis of the initial phase I trial of TRC105 demonstrated good tolerability and efficacy in cancer patients. In this report, we analyzed multiple circulating biomarkers at baseline, cycle 2 day 1 (C2D1),...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yingmiao, Starr, Mark D, Brady, John C, Dellinger, Andrew, Pang, Herbert, Adams, Bonne, Theuer, Charles P, Lee, Nam Y, Hurwitz, Herbert I, Nixon, Andrew B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101749/
https://www.ncbi.nlm.nih.gov/pubmed/24574330
http://dx.doi.org/10.1002/cam4.207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101749/
https://www.ncbi.nlm.nih.gov/pubmed/24574330
http://dx.doi.org/10.1002/cam4.207

Ejemplares similares